Get started Log in

OABI — OmniAB Share News

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Market Cap
$694.97m
Enterprise Value
$642.97m
Revenue
$18.67m

OmniAb Inc expected to post a loss of 3 cents a share - Earnings Preview
09/05/2023 19:24
Brief: Omniab Reports Fourth Quarter And Full Year 2022 Financial Results And Business Highlights
30/03/2023 21:30
OmniAb Inc expected to post earnings of 2 cents a share - Earnings Preview
28/03/2023 21:38
Cowen initiates OmniAb at 'outperform' on optimism over drug discovery platform
22/02/2023 18:34
Brief: Omniab Inc Preliminary Unaudited Cash Cash Equivalents And Marketable Securities As Of Dec 31 2022 About $88 Mln
09/01/2023 22:06
Brief: Omniab Reports Q3 2022 Financial Results
15/11/2022 12:21
Brief: Ligand Announces That Janssen Has Received Approval From European Commission For Tecvayli® (Teclistamab) For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
24/08/2022 22:18
Brief: Ligand Reports First Quarter 2022 Financial Results
04/05/2022 22:57
SPAC Avista Public Acquisition climbs on $850 mln deal with Ligand's unit
23/03/2022 20:54
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
14/12/2018 08:58
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
13/12/2018 08:58
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
12/12/2018 08:58
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
11/12/2018 08:58
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
10/12/2018 08:58
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
07/12/2018 08:58
NASDAQ TRADE HALT REASON NOT AVAILABLE
06/12/2018 08:58
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
04/12/2018 08:58
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ
03/12/2018 08:58
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
30/11/2018 08:58
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE
29/11/2018 08:58